论文部分内容阅读
目的 探讨舒肝解郁胶囊与舍曲林治疗卒中后抑郁障碍的临床疗效与安全性.方法 将128例卒中后抑郁患者按照随机数字表法分为舒肝组与舍曲林组,每组64例.比较两组治疗前与治疗4周、8周末汉密顿抑郁量表、日常生活活动能力量表评分,比较两组临床疗效及不良反应发生率.结果 舍曲林组总有效率显著高于舒肝组(χ2=8.32,P＜0.01).治疗4周末及8周末两组汉密顿抑郁量表评分均显著低于治疗前(P＜0.01),舍曲林组较舒肝组下降更显著(P＜0.05或0.01);两组日常生活活动能力量表评分均显著高于治疗前(P＜0.01),舍曲林组较舒肝组升高更显著(P＜0.01).舍曲林组不良反应发生率低于舒肝组,但差异无统计学意义(P＞0.05).结论 舍曲林及舒肝解郁胶囊治疗脑卒中后抑郁疗效均较好,但舍曲林疗效更优,安全性更高.“,”Objective To study the effects and safety of Shuganjieyu capsule with Sertraline Tablets in the treatment of post-stroke depression. Methods 128 patients with post stroke depression were selected as the subjects, randomly divided into the Shugan group and the Sertraline group, 64 cases in each group. HAMD,ADL scores, clinical effect, adverse reaction rate between the two groups before treatment, and at the end of 4,8 weeks after treatment were compared. Results Total effective rate of the Sertraline group was significantly higher than that of the Shugan group (χ2 =8.32,P＜0.01). At the end of 4, 8 weeks after treatment, HAMD scores of the two groups were all significantly lower than those before treatment (P＜0.01),Sertraline group declined more significantly than the Shugan group (P＜0.05 or 0.01); ADL scores of the two groups were all significantly higher than those before treatment (P＜0.01), Sertraline group increased more significantly than the Shugan group (P＜0.01). The adverse reaction rate of the Sertraline group was lower than that of the Shugan group, the difference was not statistic significant(P＞0.05). Conclusion Sertraline hydrochloride and Shuganjieyu capsule in the treatment of post-stroke depression have significant curative effect, but the former is more effective, with good safety.